We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Immupharma Plc | LSE:IMM | London | Ordinary Share | GB0033711010 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 2.385 | 2.21 | 2.74 | 0.00 | 08:10:28 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Finance Services | 0 | -3.81M | -0.0114 | -2.11 | 8M |
TIDMIMM TIDMAV.
RNS Number : 8466E
Immupharma PLC
21 July 2016
RNS : FOR IMMEDIATE RELEASE 21 JULY 2016
ImmuPharma PLC
("ImmuPharma" or the "Company")
TR1 NOTIFICATION OF MAJOR INTEREST BY AVIVA
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that it has received a TR-1 by Aviva plc ("Aviva"). Aviva's holding in ImmuPharma is now confirmed at a total of 11,169,942 Ordinary Shares which equates to a current position in the Company of 9.17%.
Full disclosure of the TR1 is shown below:
Hot Features
Premium
1. Identity of the issuer or ImmuPharma plc
the underlying issuer of existing
shares to which voting rights
are attached: (ii)
--------------------------------------------------------------- ---------------------------------------
2 Reason for the notification (please tick the appropriate
box or boxes):
--------------------------------------------------------------------------------------------------------
An acquisition or disposal of voting rights
------------------------------------------------------------------ ------------------------------------
An acquisition or disposal of qualifying financial
instruments which may result in the acquisition
of shares already issued to which voting rights
are attached
------------------------------------------------------------------ ------------------------------------
An acquisition or disposal of instruments with
similar economic effect to qualifying financial
instruments
------------------------------------------------------------------ ------------------------------------
An event changing the breakdown of voting rights
------------------------------------------------------------------ ------------------------------------
Other (please
specify):
----------------------------------------------------------- ----- ------------------------------------
3. Full name of person(s) Aviva plc & its subsidiaries
subject to the
notification obligation:
(iii)
------------------------------------------------------------- -----------------------------------------
4. Full name of shareholder(s) Registered Holder:
(if different from 3.):(iv)
BNY Norwich Union Nominees
Limited
628,858*
Chase (GA Group) Nominees
Limited
7,696,271*
State Street Nominees Limited
1,413,511*
*denotes direct interest
Chase (GA Group) Nominees
Limited
627,539
Chase Nominees Limited
275,292
Vidacos Nominees Limited
528,471
------------------------------------------------------------- -----------------------------------------
5. Date of the transaction 19 July 2016
and date on
which the threshold is
crossed or
reached: (v)
------------------------------------------------------------- -----------------------------------------
6. Date on which issuer 20 July 2016
notified:
------------------------------------------------------------- -----------------------------------------
7. Threshold(s) that is/are 8% to 7% Change at Direct
crossed or reached: (vi, Interest Level
vii)
------------------------------------------------------------- -----------------------------------------
8. Notified details:
--------------------------------------------------------------------------------------------------------------
A: Voting rights attached to shares (viii, ix)
--------------------------------------------------------------------------------------------------------------
Class/type Situation previous Resulting situation after
of to the triggering the triggering transaction
shares transaction
if possible
using
the ISIN
CODE
------------------- -------------------------------- -------------------------------------------------------
Number Number Number Number of % of voting
of of of voting rights (x)
Shares Voting shares rights
Rights
------------------- ------------------- ----------- ----------- ---------------------- ------------------
Direct Direct Indirect Direct Indirect
(xi) (xii)
------------------- ------------------- ----------- ----------- ---------- ---------- ------- ---------
Ordinary
Shares
GB0033711010 11,224,776 11,224,776 11,169,942 9,738,640 1,431,302 7.997% 1.175%
------------------- ----------- ----------- ---------- ---------- ------- ---------
B: Qualifying Financial Instruments
--------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
--------------------------------------------------------------------------------------------------------------
Type of financial Expiration Exercise/ Number of voting % of voting
instrument date Conversion rights that rights
(xiii) Period (xiv) may be
acquired if
the
instrument
is
exercised/
converted.
------------------- ------------------- ------------------------ ---------------------- ------------------
C: Financial Instruments with similar economic effect
to Qualifying Financial Instruments (xv, xvi)
-----------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
-----------------------------------------------------------------------------------------------
Type of financial Exercise Expiration Exercise/ Number of voting % of voting
instrument price date Conversion rights instrument rights (xix,
(xvii) period refers to xx)
(xviii)
------------------ --------- ----------- ------------ ------------------- ----------------
Total (A+B+C)
------------------------------------------------------
Number of voting rights Percentage of voting rights
------------------------ ----------------------------
11,169,942 9.172%
------------------------ ----------------------------
9. Chain of controlled undertakings through which the
voting rights and/or the
financial instruments are effectively held, if applicable:
(xxi)
---------------------------------------------------------------------------------
The voting rights are managed and controlled by Aviva
Investors Global Services Limited, with the following
chain of controlled undertakings:-
Aviva Investors Global Services Limited:
* Aviva plc (Parent Company)
* Aviva Group Holdings Limited (wholly owned subsidiary
of Aviva plc)
* Aviva Investors Holdings Limited (wholly owned
subsidiary of Aviva Group Holdings Limited)
* Aviva Investors Global Services Limited (wholly owned
subsidiary of Aviva Investors Holdings Limited)
Proxy Voting:
---------------------------------------------------------------------------------
10. Name of the proxy holder: See Section 4
--------------------------------------------- ----------------------------------
11. Number of voting rights proxy
holder will cease to hold:
--------------------------------------------- ----------------------------------
12. Date on which proxy holder will
cease to hold
voting rights:
--------------------------------------------- ----------------------------------
13. Additional information: Figures are based the revised
total number of voting rights
of 121,781,219 as per the
recent Confirmation of EIS
and VCT Qualifying Status
and Issue of Equity announcement
of 01 March 2016.
--------------------------------------------- ----------------------------------
14. Contact name: James Clark, Aviva plc
--------------------------------------------- ----------------------------------
15. Contact telephone number: 01603 683853
--------------------------------------------- ----------------------------------
-Ends-
For further information please
contact:
+ 44 (0) 20
ImmuPharma plc (www.immupharma.org) 7152 4080
Tim McCarthy, Chairman
Lisa Baderoon, Head of Investor
Relations + 44 (0) 7721
Twitter: @immupharma 413496
Panmure, Gordon & Co., (NOMAD +44 (0) 20
& Broker) 7886 2500
Fred Walsh, Duncan Monteith, Corporate
Finance
Charles Leigh-Pemberton, Corporate
Broking
Northland Capital Partners Limited
(Joint Broker)
Patrick Claridge, David Hignell,
Corporate Finance +44 (0)20 3861
Rob Rees, Corporate Broking 6631
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLDFLBLQDFLBBV
(END) Dow Jones Newswires
July 21, 2016 03:32 ET (07:32 GMT)
1 Year Immupharma Chart |
1 Month Immupharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
